Diabetes CV Trials May Look Different From SAVOR, EXAMINE In Future
Executive Summary
Outcomes trials of AstraZeneca’s saxagliptin and Takeda’s alogliptin provide reassurance on cardiovascular risks but raise other safety concerns that are difficult to interpret due to the studies’ high-risk populations and ischemia-focused endpoints.